Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

U.S. Food and Drug Administration approves Pharmacyclics Inc's IMBRUVICA


Wednesday, 12 Feb 2014 01:18pm EST 

Pharmacyclics Inc:Says that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA (ibrutinib) as a single agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.This indication is based on overall response rate (ORR). An improvement in survival or disease-related symptoms has not been established.Says 1IMBRUVICA is the first once-daily, single-agent, oral kinase inhibitor for patients with CLL who have received one prior therapy1and is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc. 

Company Quote

124.86
3.02 +2.48%
26 Dec 2014